Excessive antipsychotic dosing in 2 US state hospitals

被引:46
作者
Diaz, FJ [1 ]
de Leon, J [1 ]
机构
[1] Eastern State Hosp, Mental Hlth Res Ctr, Lexington, KY USA
关键词
D O I
10.4088/JCP.v63n1107
中图分类号
B849 [应用心理学];
学科分类号
040203 [应用心理学];
摘要
Background: This retrospective study attempted to replicate the observation that African Americans are more prone to receive excessive doses of antipsychotics, even after variables that have not been well explored in previous studies (smoking and antipsychotic potency) are controlled for. Method: The populations of 2 neighboring U.S. state hospitals, which were screened for patients who smoked, were included. The total sample comprised 316 patients from the first hospital (surveyed in 1990) and 447 patients from the second hospital (surveyed in 1992) who were taking antipsychotics and were either African American or white. An excessive antipsychotic dose (greater than 1000 mg of chlorpromazine equivalents per day) was the dependent variable in logistic regressions in all patients and in those patients with or without (DSM-III-R) schizophrenia. Results: In the total sample from both hospitals, excessive dosing was associated with schizophrenia, age under 56 years, long hospitalization duration, high-potency antipsychotics, second hospital, and depot antipsychotics. The odds of being prescribed excessive doses of typical antipsychotics were 1.8 times higher for African American than for white schizophrenic patients. African American race in schizophrenic patients appeared to be associated with the prescription of high-potency antipsychotics and with excessive dosing of this type of antipsychotic. Excessive dosing did not appear to be associated with race in nonschizophrenic patients nor in schizophrenic patients taking low-potency antipsychotics. Conclusion: Pharmacogenetic differences are not likely to explain this racial difference in prescription of excessive dosing of high-potency antipsychotics, which suggests that clinician attitudes may be a possible explanation. In future studies, pharmacogenetic tests and control for confounding factors, such as smoking, will help to establish whether racial differences in dosing are influenced by different metabolic capacities or physician biases.
引用
收藏
页码:998 / 1003
页数:6
相关论文
共 23 条
[1]
PREVALENCE OF CYP2D6 GENE DUPLICATION AND ITS REPERCUSSION ON THE OXIDATIVE PHENOTYPE IN A WHITE-POPULATION [J].
AGUNDEZ, JAG ;
LEDESMA, MC ;
LADERO, JM ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :265-269
[2]
A mechanistic approach to antiepileptic drug interactions [J].
Anderson, GD .
ANNALS OF PHARMACOTHERAPY, 1998, 32 (05) :554-563
[3]
Baldessarini RJ, 1985, CHEMOTHERAPY PSYCHIA
[4]
Benowitz NL, 1999, J PHARMACOL EXP THER, V291, P1196
[5]
EXTREMELY RAPID HYDROXYLATION OF DEBRISOQUINE - A CASE-REPORT WITH IMPLICATION FOR TREATMENT WITH NORTRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANTS [J].
BERTILSSON, L ;
ABERGWISTEDT, A ;
GUSTAFSSON, LL ;
NORDIN, C .
THERAPEUTIC DRUG MONITORING, 1985, 7 (04) :478-480
[6]
Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions [J].
Bertz, RJ ;
Granneman, GR .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :210-258
[7]
A pilot study on risperidone metabolism: The role of cytochromes P450 2D6 and 3A [J].
Bork, JA ;
Rogers, T ;
Wedlund, PJ ;
de Leon, J .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (07) :469-476
[8]
Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness [J].
Chou, WH ;
Yan, FX ;
de Leon, J ;
Barnhill, J ;
Rogers, T ;
Cronin, M ;
Pho, M ;
Xiao, V ;
Ryder, TB ;
Liu, WW ;
Teiling, C ;
Wedlund, PJ .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (02) :246-251
[9]
DAHL ML, 1995, J PHARMACOL EXP THER, V274, P516
[10]
Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital [J].
de Leon, J ;
Barnhill, J ;
Rogers, T ;
Boyle, J ;
Chou, WH ;
Wedlund, PJ .
AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (09) :1278-1280